Drug Watch: Agents in late-stage development for the treatment of type 2 diabetes mellitus (August 2008) (PDF)

Svetlana Mojsov, Ph.D., was a key part of the team that discovered the function of the hormone glucagon-like peptide 1 (GLP-1) and its role in diabetes and weight loss.

Almost half of adults surveyed by KFF would be interested in taking a weight-loss drug, including many who say they only want to lose a little weight.

Researchers say capping insulin costs at $35 a month has the potential to lower events and costs related to diabetes, such as amputations, vision loss, and heart attacks.

Sara Izadi, Pharm.D., of Capital Rx, talks about Rx Reverse, an integrated clinical program designed to help members reverse diabetes and fight obesity.

An analysis by Biosimilars Council has found that the reference product Lantus accounts for 54% of new prescriptions and is 78% of total market volume but demand for the unbranded interchangeable insulin glargine is increasing.

Longer-acting growth hormone reduces frequency of injections. It will be available in August.